Literature DB >> 10947912

Management of patients with prosthetic heart valves: potential impact of valve site, clinical characteristics, and comorbidity.

N Mercadante1.   

Abstract

Nearly four decades have passed since the first mechanical prosthetic aortic valve was placed. Since then several design changes and modifications have been made to improve longevity and hemodynamics and reduce thrombogenicity. Despite these advances thromboembolism remains the major problem for mechanical prosthetic valves. The type and the position of the prosthetic valve and several clinical characteristics such as age greater than 70, atrial fibrillation, depressed left ventricular systolic function, left atrial enlargement, left atrial thrombus and a prior history of systemic embolization influence the risk of thromboembolism and the level of anticoagulation needed to prevent this complication. Through clinical experience guidelines have been developed by the American College of Chest Physicians to determine the optimal level of anticoagulation needed to lower the thromboembolic rate with an acceptable hemorrhagic event rate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10947912     DOI: 10.1023/a:1018742620401

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  19 in total

1.  AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves.

Authors:  J Acar; B Iung; J P Boissel; M M Samama; P L Michel; J P Teppe; J C Pony; H L Breton; D Thomas; R Isnard; G de Gevigney; E Viguier; A Sfihi; G Hanania; M Ghannem; A Mirode; C Nemoz
Journal:  Circulation       Date:  1996-11-01       Impact factor: 29.690

Review 2.  Modern management of prosthetic valve anticoagulation.

Authors:  D J Tiede; R A Nishimura; D A Gastineau; C J Mullany; T A Orszulak; H V Schaff
Journal:  Mayo Clin Proc       Date:  1998-07       Impact factor: 7.616

Review 3.  Prosthetic heart valves.

Authors:  W Vongpatanasin; L D Hillis; R A Lange
Journal:  N Engl J Med       Date:  1996-08-08       Impact factor: 91.245

Review 4.  Antithrombotic therapy in mechanical and biological prosthetic heart valves and saphenous vein bypass grafts.

Authors:  P D Stein; J J Collins; A Kantrowitz
Journal:  Chest       Date:  1986-02       Impact factor: 9.410

5.  Mitral valve Carpentier-Edwards bioprosthetic replacement, thromboembolism, and anticoagulants.

Authors:  Y A Louagie; J Jamart; P Eucher; M Buche; J C Schoevaerdts
Journal:  Ann Thorac Surg       Date:  1993-10       Impact factor: 4.330

Review 6.  Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses.

Authors:  S C Cannegieter; F R Rosendaal; E Briët
Journal:  Circulation       Date:  1994-02       Impact factor: 29.690

7.  Unexpected findings concerning thromboembolic complications and anticoagulation after complete 10 year follow up of patients with St. Jude Medical prostheses.

Authors:  D Horstkotte; H Schulte; W Bircks; B Strauer
Journal:  J Heart Valve Dis       Date:  1993-05

8.  Trial of different intensities of anticoagulation in patients with prosthetic heart valves.

Authors:  J N Saour; J O Sieck; L A Mamo; A S Gallus
Journal:  N Engl J Med       Date:  1990-02-15       Impact factor: 91.245

9.  Optimal oral anticoagulant therapy in patients with mechanical heart valves.

Authors:  S C Cannegieter; F R Rosendaal; A R Wintzen; F J van der Meer; J P Vandenbroucke; E Briët
Journal:  N Engl J Med       Date:  1995-07-06       Impact factor: 91.245

10.  Comparison of two levels of anticoagulant therapy in patients with substitute heart valves.

Authors:  R Altman; J Rouvier; E Gurfinkel; O D'Ortencio; R Manzanel; L de La Fuente; R G Favaloro
Journal:  J Thorac Cardiovasc Surg       Date:  1991-03       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.